Intagra
Intagra Price range: $ 39,00 through $ 210,00
Back to products
Isoniazid
Isoniazid Price range: $ 45,00 through $ 444,00

Isofair

Price range: $ 50,00 through $ 486,00

Isofair is a powerful systemic retinoid specifically formulated to combat severe and recalcitrant forms of nodular acne. It works by significantly reducing the size and output of the skin’s oil glands to prevent the formation of deep-seated breakouts. This medication is an ideal solution for those seeking long-term relief from persistent skin conditions that have not responded to conventional therapies. By targeting inflammation at its source, it helps to promote a clearer complexion and effectively reduces the risk of permanent scarring. Consistent use as directed supports the restoration of skin health and provides a reliable path toward a smoother, blemish-free appearance.

Active substance: Isotretinoin
SKU: Isofair Category:
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Isofair belongs to a group of systemic retinoids derived from vitamin A, engineered to treat severe skin conditions. It is prescribed exclusively for severe, recalcitrant nodular acne that has failed to clear following standard treatment regimens, including topical therapies and systemic antibacterial agents.

Due to the potency of its active ingredient, isotretinoin, treatment requires strict compliance with federal risk evaluation protocols and direct clinical monitoring by a licensed prescriber in the United States.

Property Specification
Active Ingredient Isotretinoin (13-cis-retinoic acid)
Therapeutic Class Systemic Retinoid (AHFS: Retinoid)
Dosage Form Oral soft gelatin capsule
Route of Administration Oral
Prescription Status Prescription (Rx) only; subject to FDA iPLEDGE REMS program
Primary Purpose Treatment of severe recalcitrant nodular acne

Clinical Profile and Operational Guidelines

How the drug works

Warning: Isofair alters cellular mechanisms throughout the body and must be managed with clinical oversight. The active constituent, isotretinoin, works by suppressing sebaceous gland activity and reducing overall gland size. By inhibiting sebum production, the medication deprives Cutibacterium acnes (formerly Propionibacterium acnes) of the lipid nutrient substrate required for proliferation. Furthermore, isotretinoin normalizes keratinization within the follicular epithelium, preventing the formation of microcomedones and reducing systemic inflammatory signaling in the dermis. Unlike topical acne formulations, systemic isotretinoin alters the follicular microenvironment long-term, which can lead to prolonged remission after a single structured treatment course.

Main uses

Isofair is indicated solely for the treatment of severe, recalcitrant nodular acne in non-pregnant patients. A nodule is defined as an inflammatory lesion measuring 5 mm or greater in diameter. Medical guidelines mandate that this medication be reserved for cases where traditional regimens–including systemic antibiotics–have failed to induce acceptable clinical improvement. Prescribers may occasionally consider isotretinoin for severe, therapy-resistant forms of hidradenitis suppurativa or recalcitrant rosacea; however, these applications represent off-label uses not explicitly designated under standard FDA labeling and require specialized dermatological assessment of risks versus benefits.

Important precautions

Warning: High Risk of Severe Birth Defects. Isotretinoin is extremely teratogenic. Exposure during pregnancy causes severe structural anomalies including craniofacial, cardiovascular, thymic, and central nervous system defects, as well as spontaneous abortion or premature delivery. Female patients of childbearing potential must enroll in the mandatory FDA-approved REMS program (iPLEDGE), utilize two independent forms of effective contraception simultaneously for at least one month prior to initiating therapy, throughout the duration of treatment, and for one full month following cessation. Regular negative laboratory pregnancy tests are legally mandatory before each prescription refill. Prescribers must also screen for psychiatric vulnerabilities, as isotretinoin has been linked to depression, psychosis, rare suicidal ideation, and mood alterations.

Dosing schedule

The total dosage of Isofair is calculated individually based on body weight and clinical response. The recommended initial therapeutic range is 0.5 to 1.0 mg/kg per day, administered in two divided doses. For patients with severe disease or initial chest and back involvement, initial titration may start at lower dosages to minimize flare-ups. A standard course of therapy usually spans 15 to 20 weeks. Clinical evidence indicates that achieving a cumulative total dose of 120 to 150 mg/kg per course yields optimal long-term remission rates and minimizes relapse. Capsules must be swallowed whole with liquid; they should never be chewed, crushed, or dissolved.

What happens in the body

Following oral administration, absorption of isotretinoin varies significantly depending on gastric contents. Peak plasma concentrations are typically reached within 2 to 4 hours post-ingestion. Taking the capsule alongside a high-fat meal doubles systemic bioavailability compared to administration under fasting conditions. Isotretinoin is greater than 99.9% bound to plasma proteins, predominantly serum albumin. Metabolism occurs primarily in the liver via cytochrome P450 enzymes (specifically CYP2C8, CYP2C9, CYP3A4, and CYP2B6), forming the principal metabolite, 4-oxo-isotretinoin. The terminal elimination half-life of parent isotretinoin averages between 10 and 20 hours, whereas its primary metabolite exhibits an average half-life of approximately 90 hours. Excretion occurs in roughly equal proportions via renal and biliary routes.

Adverse reactions

Adverse events associated with Isofair are widespread due to systemic retinoid activity. Cheilitis (extreme dry lips) occurs in almost all patients. Dry skin, pruritus, mucosal dryness, xerophthalmia (dry eyes), and epistaxis (nosebleeds) are extremely common. Musculoskeletal complaints, including myalgia, arthralgia, and back pain, frequently occur, particularly in physically active individuals. Laboratory abnormalities include transient elevations in serum liver transaminases, elevated baseline fasting triglycerides, decreased high-density lipoproteins (HDL), and elevated erythrocyte sedimentation rates. Less common but severe side effects include night blindness, corneal opacities, inflammatory bowel disease, and benign intracranial hypertension.

What not to combine

Warning: Serious Drug Interactions. Concomitant administration of Isofair with specific drug classes can cause severe adverse clinical events:

  • Tetracyclines (e.g., doxycycline, minocycline, tetracycline): Combined use is strictly contraindicated due to a significantly increased risk of developing pseudotumor cerebri (benign intracranial hypertension), which can lead to permanent vision loss.
  • Vitamin A Supplements: Co-administration must be avoided because cumulative toxicity risks mimic hypervitaminosis A symptoms.
  • Progestin-Only Micro-Dosed Oral Contraceptives: Micro-dosed “minipills” may be rendered inadequate for birth control when combined with retinoid regimens; prescribers must select robust primary contraceptive methods.
  • Systemic Corticosteroids: Combining corticosteroids with retinoids may increase the risk of bone loss or osteoporosis.

What to avoid while taking it

Patients taking Isofair must avoid taking excess dietary supplements containing Vitamin A. Consuming alcohol should be strictly limited or avoided entirely throughout treatment due to compound metabolic stress on the liver and potential exacerbation of hypertriglyceridemia. Furthermore, patients are strictly prohibited from donating blood during therapy and for at least one month after stopping Isofair, to prevent transfusing blood containing retinoid molecules to a pregnant recipient. Patients should avoid aggressive cosmetic skin procedures–such as laser therapy, dermabrasion, or chemical peels–and body waxing during therapy and for six months post-treatment, due to an elevated risk of severe scarring and delayed cutaneous healing.

Pregnancy, breastfeeding, and other groups

Isofair is strictly contraindicated in women who are pregnant, planning to become pregnant, or nursing. It is classified as FDA Pregnancy Category X. Breastfeeding must not be undertaken during therapy because retinoids pass into breast milk and pose severe toxicity risks to the infant. The safety and efficacy of isotretinoin in pediatric patients under 12 years of age have not been established. In older adolescents, prescribers must monitor skeletal growth, as premature epiphyseal closure has been documented with systemic retinoid exposure. Elderly populations rarely present with recalcitrant nodular acne, but senior patients prescribed this drug require vigilant hepatic and lipid profile monitoring.

If you skip a dose

If a scheduled dose of Isofair is missed, the patient should skip that specific dose entirely and take the next dose at the regular scheduled time. Patients must never double the dose or take extra capsules to make up for a missed administration. Maintaining a uniform dosing routine helps stabilize blood plasma levels, but double-dosing increases acute toxicity risks without providing therapeutic advantage.

Red flags

Patients must monitor their body closely for life-threatening or severe adverse reactions. Immediate medical intervention is mandatory if systemic toxicity signs emerge during therapy. Below is a summary of critical warning symptoms that necessitate immediate evaluation by emergency care personnel.

Symptom Category Critical Warning Sign Immediate Action Required
Central Nervous System Severe headache, nausea, vomiting, visual disturbances, or papilledema Discontinue medication; seek emergency medical care (possible Intracranial Hypertension).
Psychiatric Health Severe depression, unexpected crying spells, suicidal ideation, or self-harm thoughts Stop medication immediately; contact a physician or emergency crisis care.
Gastrointestinal System Severe abdominal pain, rectal bleeding, or severe hemorrhagic diarrhea Seek urgent medical evaluation (possible Inflammatory Bowel Disease).
Hepatic / Pancreatic Yellowing of eyes/skin (jaundice), dark urine, or severe epigastric pain radiating to back Seek immediate emergency department evaluation (Hepatotoxicity / Acute Pancreatitis).
Hypersensitivity Swelling of face, tongue, throat, severe skin rash with blistering or peeling skin Call 911 or visit the nearest emergency medical facility immediately.

Patient FAQ and Regulatory Summary

Common questions

Why is routine blood testing required throughout my Isofair prescription?

Routine baseline and ongoing blood tests are medically necessary to ensure your liver and cardiovascular system remain safe during therapy. Isotretinoin is metabolized by hepatic enzymes and significantly affects lipid metabolism. Your prescriber will test your fasting serum lipid profile (triglycerides and cholesterol) and liver transaminases (ALT/AST) prior to treatment, four weeks after starting, and periodically thereafter to prevent hepatotoxicity and acute pancreatitis.

What should I do if I develop severe cutaneous dryness or lip fissures?

Mucocutaneous dryness is an expected pharmacologic effect of systemic retinoids. You should preemptively apply topically approved emollient lip balms and non-comedogenic skin moisturizers multiple times daily. Avoid harsh skin cleansers, exfoliants, or topical acne products containing benzoyl peroxide or salicylic acid. If dryness causes skin cracking or localized infection, consult your dermatologist for specialized barrier ointments.

Is night vision loss permanent if it occurs during Isofair therapy?

Decreased night vision (night blindness) can occur suddenly during isotretinoin therapy due to retinoid effects on the ocular visual pigments. While this effect frequently resolves after drug discontinuation, it can persist indefinitely in rare instances. You must exercise extreme caution when driving or operating machinery at night and report any sudden visual changes to your prescriber immediately.

Why must high-fat meals be consumed with every Isofair dose?

The active drug, isotretinoin, is highly lipophilic (fat-soluble). Consuming the soft capsule alongside a meal containing dietary lipids (fat) substantially increases intestinal absorption efficiency, doubling the active concentration entering your bloodstream compared to taking it on an empty stomach. Inadequate fat intake alongside dosing can result in sub-therapeutic blood levels and treatment failure.

Can I undergo laser hair removal or skin resurfacing while taking Isofair?

No. Systemic retinoid therapy impairs epidermal healing and alters collagen remodeling pathways in the skin tissue. Undergoing invasive cutaneous procedures–such as laser therapy, mechanical dermabrasion, or chemical skin peels–during treatment or within six months after stopping Isofair carries a high risk of abnormal scarring, hypertrophic keloid formation, and prolonged tissue erythema.

In accordance with FDA requirements.

This material is educational. Only a licensed prescriber can determine whether a medication is appropriate for you.

Additional information
Dosage

10mg

,

20mg

Package

20 pills

,

30 pills

,

60 pills

,

90 pills

,

120 pills

,

180 pills

,

270 pills

,

360 pills

Ενεργός Ουσία